Puma Biotechnology director Wilson Troy Edward sold 5,000 shares at $9.10 each on Sept. 14. The transaction represented about 8.4% of his prior holding, while he retained 54,750 shares afterward, giving investors a precise view of the reported insider transaction and his remaining ownership.
Key Highlights
- Wilson Troy Edward held 54,750 Puma Biotechnology shares after the transaction.
- The sale represented about 8.4% of his prior Puma Biotechnology shareholding.
- The transaction occurred on Sept. 14, 2026, under transaction code S.
PUMA BIOTECHNOLOGY, INC. (NASDAQ: PBYI) director Wilson Troy Edward sold 5,000 shares at $9.10 per share. The transaction took place on Sept. 14, 2026, and represents about 8.4% of his prior shareholding.
Sale Equals 8.4% of
Prior Holding The transaction represented about 8.4% of Wilson Troy Edward’s prior shares held in PUMA BIOTECHNOLOGY, INC. The reported post-transaction holding was 54,750 shares.
FAQs
Q: How many Puma Biotechnology shares did Wilson Troy Edward sell?
A: Wilson Troy Edward sold 5,000 Puma Biotechnology shares at $9.10 per share. The transaction was reported on Sept. 14, 2026.
Q: How many PUMA BIOTECHNOLOGY shares did the director retain?
A: Wilson Troy Edward owned 54,750 PUMA BIOTECHNOLOGY shares after the transaction. He is identified as a director of the company.
Q: What does transaction code S mean for the PUMA BIOTECHNOLOGY sale?
A: The reported sale represented about 8.4% of Wilson Troy Edward’s prior holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.